Lexington, MA-based Cubist Pharmaceuticals announced it will pay $4.7 million, plus another $1 million in research and operating costs, for an exclusive option to buy Seattle’s Illumigen Biosciences. Illumigen’s lead compound is a protein-based treatment for hepatitis C. If Cubist exercises its option it will pay $9 million upfront, plus development and regulatory milestone payments that could surpass $330 million.
Why is this story so short? Because it's a news brief
from our News Xpress section,
which brings you quick takes on
the latest Boston-area biz/tech news as it unfolds throughout
the day.
Where do I find more in-depth news and analysis about the
business of technology in the Boston area? We've got
plenty of that right on our
home page and in our
archives.
Who the heck are the Xconomists mentioned on your
homepage? They're an elite group of movers and shakers in
the local tech scene who've generously agreed to share
their insights and opinions with Xconomy's readers. Here's a
complete list of them; to read their posts, have a look
here and
here.
Come to think of it, what does "Xconomy" mean in the
first place? Xconomy is a word we made up to evoke the
exponential economy—the realm of business and innovation
characterized by exponential technological growth and
responsible for an increasing share of productivity
and overall economic growth.
(Not everybody likes the name, by the way. We're okay with that.)
We're a small group of professional journalists dedicated to
bringing you the most important news about New England's role
in the exponential economy. More on our mission and team
here.
Share
